tkm-080301
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01262235)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase PLK1ANTISENSE INHIBITOR
PLK1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tkm-080301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02191878 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Arbutus Biopharma Corporation |
| NCT01437007 | Phase 1 | Aug 26, 2011 | National Cancer Institute (NCI) |
| NCT01262235 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | Arbutus Biopharma Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arbutus Biopharma Corporation | For profit | 2 | 2 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1